If you have pneumonitis with Keytruda, your doctor might prescribe corticosteroid treatment for you. Additionally, your doctor may recommend that you temporarily or permanently stop taking Keytruda.

The company is paying China-based biotech LaNova Medicines $588 million for the kind of dual-pronged antibody drug that ...

In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...

There isn't enough evidence to support the use of Merck & Co/MSD's Keytruda in combination with chemotherapy as a first-line treatment for advanced triple negative breast cancer, according to the ...

Keytruda in early-stage triple-negative breast cancer led to immune-related adverse effects, including severe GI issues and ...

The KEYNOTE-689 trial assessing Keytruda (pembrolizumab) for the perioperative treatment of newly diagnosed stage 3 or 4A, resected, locally advanced head and neck squamous cell carcinoma met its ...

Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...

While some of the initial excitement around immunotherapies has waned, companies—particularly smaller biotechs—are developing ...

During a Case-Based Roundtable® event, Matthew Campbell, MD, MS, moderated a discussion on treatment for a 61-year-old ...

"These approvals underscore the continued expansion of the use of KEYTRUDA in diverse patient populations and treatment settings with utility of KEYTRUDA ranging from earlier lines of therapy to ...

Michael Okunewitch, an analyst from Maxim Group, maintained the Buy rating on Citius Pharmaceuticals (CTXR – Research Report). The ...

The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health business.